Regulatory Roundup: FDA Holds Workshop on Orphan Drugs - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Holds Workshop on Orphan Drugs

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA will hold its fourth orphan-drug designation workshop for academics, biotechnology companies, and those unfamiliar with the orhan-drug designation process Feb. 28–Mar. 1, 2011, in Claremont, California, in collaboration with Keck Graduate Institute, according to an agency announcement. The workshop will focus on the process used by FDA to grant orphan-drug designation to drug products intended to treat rare diseases. Three similar workshops were held in 2010.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here